Allakos

$90.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$6.88 (+8.18%) As of 1:44 PM EDT today

Why Robinhood?

You can buy or sell Allakos and other stocks, options, and ETFs commission-free!

About ALLK

Allakos Inc. Common Stock, also called Allakos, is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. Read More The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA. The listed name for ALLK is Allakos Inc. Common Stock.

CEO
Robert Alexander
Employees
90
Headquarters
Redwood City, California
Founded
2012
Market Cap
4.35B
Price-Earnings Ratio
Dividend Yield
Average Volume
235.88K
High Today
$93.00
Low Today
$86.00
Open Price
$87.10
Volume
858.69K
52 Week High
$139.99
52 Week Low
$41.61

Collections

ALLK Earnings

-$0.80
-$0.53
-$0.27
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Available Nov 9, Pre-Market

You May Also Like